Des IGF 1mg/vial 1 Vial by Bio-Peptide

Usage

1. Reconstitute the lyophilized Des (1-3) IGF-1 powder by injecting bacteriostatic water (0.9% benzyl alcohol) slowly down the inner vial wall — use 1–2 mL per 1 mg vial — and swirl gently; never shake or vortex.
2. Calculate your pre-workout dose (typically 20–60 mcg) and draw the appropriate volume into a 29–31 gauge insulin syringe, then expel any air bubbles completely.
3. Select the specific target muscle you are training that session — Des IGF-1's anabolic effect is site-restricted, so intramuscular injection into the exact muscle you intend to hypertrophy is critical.
4. Administer the injection 15–20 minutes before your working sets begin, inserting the needle at 45–90° into the muscle belly and delivering the solution slowly over 5–10 seconds.
5. Begin your training session immediately within the injection window to synchronize mechanical load with peak IGF-1R receptor engagement at the target site.
6. After training, recap the syringe safely, label the reconstituted vial with the preparation date, and return it to refrigerator storage (2–8 °C); discard any unused solution after 28 days.

Warnings

Frequently asked questions

When should you use IGF-1 DES instead of IGF-1 LR3 for muscle growth?

Choose IGF-1 DES when your goal is compartmentalized, site-specific hypertrophy rather than systemic anabolism. IGF-1 LR3 carries a 13-amino-acid extension that reduces IGFBP binding and extends circulating half-life to roughly 20–30 hours, distributing its effect broadly. Des IGF-1's half-life of approximately 20–30 minutes confines receptor activation almost entirely to the injected tissue — making it the more targeted tool for lagging muscle groups.

Why is injecting IGF-1 DES pre-workout more effective than post-workout?

Injecting 15–20 minutes before training synchronizes the peptide's peak receptor engagement with the mechanical stimulus of the workout. During this window, Des IGF-1 activates IGF-1R-mediated PI3K/Akt/mTOR signalling in the target muscle; the subsequent resistance training then amplifies satellite cell recruitment at the same site. Post-workout injection misses this synergistic overlap because the peptide's ultra-short half-life means it has largely cleared before the training stimulus arrives.

How short is the active half-life of Des (1-3) IGF-1 compared to other IGF-1 variants?

Des (1-3) IGF-1 has an estimated half-life of 20–30 minutes in biological systems, based on pharmacokinetic modelling studies of truncated IGF-1 analogues. This contrasts sharply with native IGF-1 (half-life ~12–15 hours bound to IGFBPs) and IGF-1 LR3 (~20–30 hours). The brevity of Des IGF-1's activity window is a feature, not a limitation — it is the structural basis for its site-specific action.

How do you reconstitute and store Bio-Peptide Des (1-3) IGF-1 1mg/vial after opening?

Reconstitute the lyophilized powder with bacteriostatic water (0.9% benzyl alcohol) — typically 1–2 mL per vial — injecting the diluent slowly down the vial wall to avoid foaming. Once reconstituted, store the vial at 2–8 °C (refrigerated, not frozen) and use within 28 days. Mark the date of reconstitution on the vial. Discard any solution that appears cloudy or contains visible particulates.

What syringe type and injection technique should be used for Des (1-3) IGF-1 site injections?

Use a 29–31 gauge insulin syringe (0.5 mL capacity) for intramuscular injection directly into the target muscle belly. Draw the calculated volume carefully, expel air bubbles, and inject into the pre-trained or pre-training muscle at a 45–90° angle depending on tissue depth. Rotating injection sites within the same muscle group reduces localized irritation and maintains tissue integrity over a full protocol cycle. (2) angle_used

Manufacturer

Bio-Peptide's place in the European research-peptide landscape was not secured through volume alone — it was shaped by an operational constraint the company imposed on itself before scaling production: every vial bearing the Bio-Peptide name had to clear two distinct external laboratory checkpoints before it could leave the facility. The first checkpoint is HPLC (High-Performance Liquid Chromatography) analysis performed by an independent laboratory, confirming both the molecular sequence identity and the purity percentage of the peptide in that specific batch. The second is a LAL (Limulus Amebocyte Lysate) endotoxin assay, establishing that bacterial contamination levels fall within acceptable safety thresholds for injectable research compounds. What is notable is that these requirements predate much of the formal regulatory scrutiny that later reached the sector; they were not retrofitted in response to external pressure but were baked into the company's founding production model. Each certificate of analysis is batch-traceable, meaning a specific document corresponds to a specific production run — not a generic template applied across multiple products. Bio-Peptide's lyophilization infrastructure, developed under cGMP-aligned process controls, ensures that peptides including Des (1-3) IGF-1 retain structural integrity through the full logistics chain from manufacture to end use.